MeiraGTx and Hologen AI Form $430 Million Joint Venture to Accelerate AI-Driven Gene Therapy for Parkinson's Disease

MeiraGTx and Hologen AI Forge Groundbreaking Partnership

In a significant move that merges biotechnology with artificial intelligence, MeiraGTx Holdings plc has announced a strategic collaboration with Hologen Limited, a developer of multi-modal generative AI foundation models for clinical medicine and pharmaceutical drug development. This partnership, valued at $430 million, aims to accelerate the development of gene therapies for neurological disorders, particularly Parkinson's disease 1

1

2

2

3

3

.

Financial Details and Joint Venture Formation

The collaboration involves a substantial financial commitment:

• MeiraGTx will receive an upfront cash payment of $200 million 1

  1

  2

  2

  3

  3

  .
• A joint venture, Hologen Neuro AI Ltd, will be formed with additional funding of up to $230 million from Hologen 1

  1

  2

  2

  3

  3

  .
• The joint venture will fully finance the development of AAV-GAD for Parkinson's disease through commercialization 1

  1

  2

  2

  .
• MeiraGTx will retain 30% ownership in the joint venture and lead all clinical development and manufacturing 1

  1

  2

  2

  3

  3

  .

Focus on AAV-GAD for Parkinson's Disease

The primary focus of this collaboration is to expedite the Phase 3 development of AAV-GAD, a gene therapy candidate for Parkinson's disease:

• AAV-GAD has shown promising results in previous clinical studies, demonstrating significant improvements in Parkinson's disease rating scales and quality of life measures 2

  2

  .
• The program is Phase 3 ready, with commercial manufacturing ongoing in-house at MeiraGTx 1

  1

  .

AI Integration in Drug Development and Manufacturing

Hologen's AI capabilities will play a crucial role in optimizing MeiraGTx's operations:

• Hologen will contribute its multi-modal generative foundation models (LMMs) to the joint venture 1

  1

  3

  3

  .
• The AI technology will be used to enhance MeiraGTx's proprietary manufacturing capabilities 1

  1

  .
• This integration aims to create the first neuro-AI clinical drug development company 1

  1

  3

  3

  .

Expansion Beyond Parkinson's Disease

While the AAV-GAD program for Parkinson's disease is the primary focus, the collaboration extends to other areas:

• The joint venture will also fund earlier-stage clinical programs in the central nervous system (CNS) 1

  1

  2

  2

  .
• This includes the development of AAV-BDNF for genetic obesity 1

  1

  .

Impact on MeiraGTx's Operations and Stock

The collaboration has significant implications for MeiraGTx:

• Hologen will acquire a minority stake in MeiraGTx's manufacturing subsidiary and contribute to its annual funding 1

  1

  2

  2

  3

  3

  .
• MeiraGTx will enter into exclusive clinical and commercial manufacturing supply agreements with the joint venture 1

  1

  3

  3

  .
• The announcement led to a substantial increase in MeiraGTx's stock price, with reports indicating a surge of up to 24.80% 1

  1

  2

  2

  .

Closing and Future Prospects

The transactions are expected to close in the second calendar quarter of 2025, subject to customary closing conditions 1

1

2

2

. This collaboration represents a significant step forward in the integration of AI with gene therapy development, potentially transforming the approach to treating neurological disorders and optimizing biopharmaceutical manufacturing processes.